Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS 986012 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 10 Dec 2018 Planned End Date changed from 17 Oct 2018 to 24 Oct 2019.
    • 10 Dec 2018 Planned primary completion date changed from 16 Oct 2018 to 23 Oct 2019.
    • 29 Dec 2017 Planned End Date changed from 16 Sep 2018 to 17 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top